The last time I wrote about 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), it was in a Seeking Alpha article entitled “4d Molecular Therapeutics: Several Value Inflection Points To Watch In 2024.” In ...
4D Molecular Therapeutics announced an acceleration in the timeline for its 4FRONT-1 Phase 3 trial data readout of the 4D-150 treatment for wet age-related macular degeneration (AMD), now expected in ...
D Molecular Therapeutics (FDMT) offers attractive growth potential with strong cash reserves and promising late-stage gene ...
TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular ...
SAN FRANCISCO--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a leader in next-generation gene therapy vector discovery and product development, today announced a collaboration and license ...
Please provide your email address to receive an email when new articles are posted on . Astellas has gained the rights to utilize 4DMT’s R100 vector to deliver its unique genetic payloads. Astellas is ...
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is one of the stocks Jim Cramer answered questions about recently. A caller asked Cramer for his opinion on the stock, and noted that it was rated a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback